TY - GEN
T1 - Impact of atorvastatin on triple-negative and hormone receptor-positive breast cancer cells- an in vitro study
AU - Hewa Marambage, Kasuni
AU - Jinadasa, A. G.R.Greshamali
AU - Ekanayake, Sagarika
AU - Wageesha, N. D.Amal
PY - 2024
Y1 - 2024
N2 - Background: Elevated levels of serum lipid parameters are identified to implicate oncogenesis.Studies on the impact of statins on breast cancer cells as treatment options by altering lipidmetabolism holds significance.Objective: To identify anticancer effects of atorvastatin on triple-negative and hormonereceptorpositive breast cancer cells in vitro.Methods: A concentration series of atorvastatin calcium (10-160 μmoldm-3) was prepared in cellculture media (2 mg atorvastatin calcium +2 μL dimethyl sulfoxide +2 mL media). The testconcentrations were treated on seeded triple negative MDA-MB-231 and hormone receptorspositive MCF7 cells (6 replicates). The treated cells were incubated at 37 ° for 24, 48 and 72hours and percentage cell viability were assessed with sulforhodamine B (SRB) assay. The halfmaximal inhibitory concentrations (IC50) of atorvastatin were calculated at 24, 48 and 72 hours,compared to negative controls containing complete cell culture media and 0.1% DMSO.Results: The IC50 for triple-negative MDA-MB-231 cells were 86.9, 15.7 and 1.1 μmoldm-3for24, 48 and 72 hours of incubation respectively, where the percentage viability vs concentrationcurves were derived with R2 > 0.9 respectively. No significant effect was observed at 24 hoursfor MCF7 cells compared to positive control. IC50 for MCF7 for 48 and 72 hours were 99.2 and57.8 μmoldm3 respectively, where the percentage viability vs concentration curves were derivedwith R2 >0.9. At 24hour IC50 for the positive control were 4.0 x 10-3 μmoldm-3for MDA-MB-231and 135.9 x 10-3 μmoldm-3 for MCF7.Conclusions: The SRB assay indicated that atorvastatin exerts potential anticancer effects ontriple-negative breast cancer cells than hormone receptor-positive breast cancer cells in vitrowithin 24 hours. However, upon prolonged incubation, atorvastatin exerts cytotoxicity againstboth MDAMB-231 and MCF7 cells. Further studies on the same will be beneficial to identify thepotential therapeutic impact of statins on breast cancer cells.Acknowledgements: University Research Grant, University of Sri Jayewardenepura, Sri LankaASP/01/RE/AHS/2022/91
AB - Background: Elevated levels of serum lipid parameters are identified to implicate oncogenesis.Studies on the impact of statins on breast cancer cells as treatment options by altering lipidmetabolism holds significance.Objective: To identify anticancer effects of atorvastatin on triple-negative and hormonereceptorpositive breast cancer cells in vitro.Methods: A concentration series of atorvastatin calcium (10-160 μmoldm-3) was prepared in cellculture media (2 mg atorvastatin calcium +2 μL dimethyl sulfoxide +2 mL media). The testconcentrations were treated on seeded triple negative MDA-MB-231 and hormone receptorspositive MCF7 cells (6 replicates). The treated cells were incubated at 37 ° for 24, 48 and 72hours and percentage cell viability were assessed with sulforhodamine B (SRB) assay. The halfmaximal inhibitory concentrations (IC50) of atorvastatin were calculated at 24, 48 and 72 hours,compared to negative controls containing complete cell culture media and 0.1% DMSO.Results: The IC50 for triple-negative MDA-MB-231 cells were 86.9, 15.7 and 1.1 μmoldm-3for24, 48 and 72 hours of incubation respectively, where the percentage viability vs concentrationcurves were derived with R2 > 0.9 respectively. No significant effect was observed at 24 hoursfor MCF7 cells compared to positive control. IC50 for MCF7 for 48 and 72 hours were 99.2 and57.8 μmoldm3 respectively, where the percentage viability vs concentration curves were derivedwith R2 >0.9. At 24hour IC50 for the positive control were 4.0 x 10-3 μmoldm-3for MDA-MB-231and 135.9 x 10-3 μmoldm-3 for MCF7.Conclusions: The SRB assay indicated that atorvastatin exerts potential anticancer effects ontriple-negative breast cancer cells than hormone receptor-positive breast cancer cells in vitrowithin 24 hours. However, upon prolonged incubation, atorvastatin exerts cytotoxicity againstboth MDAMB-231 and MCF7 cells. Further studies on the same will be beneficial to identify thepotential therapeutic impact of statins on breast cancer cells.Acknowledgements: University Research Grant, University of Sri Jayewardenepura, Sri LankaASP/01/RE/AHS/2022/91
UR - https://site.pdn.ac.lk/ipurse/2024/docs/iPURSE%20preceedings%202024.pdf
M3 - Conference paper
SP - 88
BT - Impact of atorvastatin on triple-negative and hormone receptor-positive breast cancer cells- an in vitro study
ER -